Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Rogers Media Partners With AstraZeneca Canada And Physical And Health Education Canada To Promote New Children's Wellness Program At My BestTM
Rogers Media is proud to join AstraZeneca Canada and Physical and Health Education Canada (PHE Canada) as a presenting partner of the school-based children"s wellness initiative, At My Best. The program addresses three key areas of wellness-physical, nutritional and emotional-and empowers teachers, parents and caregivers to inspire and motivate children and their families to make healthier choices today and develop lifelong healthy habits.
generic viagra online
Health Savings Account Enrollment Reaches Eight Million
Eight million Americans are covered by Health Savings Account (HSA)-eligible insurance plans, an increase of more than 31 percent since last year, a new census released today by America"s Health Insurance Plans (AHIP) finds. Health Savings Accounts were authorized starting in January 2004. Since then, AHIP has conducted a periodic census of its members participating in the HSA/high-deductible health plan (HDHP) market.
News of the day
NY Times Interview With Sebelius: "I'm Very Encouraged"
Health and Human Services Secretary Kathleen Sebelius, spoke to The New York Times about the state of health care reform on Capitol Hill during a 15-minute interview.
Medical Devices

Sutent Significantly Improved Progression-Free Survival For Patients With Advanced Pancreatic Islet Cell Tumours

Pfizer announced preliminary results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic islet cell tumours, also known as pancreatic neuroendocrine tumours, which is a different type of cancer than the more common pancreatic adenocarcinoma. Study findings demonstrated that median progression-free survival (PFS) was 11.1 months in patients treated with Sutent compared to 5.5 months in patients treated with placebo. Researchers today presented these data at the 11th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The independent Data Monitoring Committee (DMC) recommended halting the trial earlier this year because Sutent showed significant benefit and the study had met its primary endpoint. Full analysis of the data is ongoing. "In this study, Sutent demonstrated an impressive improvement in progression-free survival for patients with pancreatic islet cell tumours," said Dr. Eric Raymond, MD, PhD, Professor of Medical Oncology and Head of University Department of Medical Oncology (Service Inter Hospitalier de Cancerologie) Bichat-Beaujon, Clichy, France, and lead investigator on this sunitinib Phase 3 study. "This is encouraging news for patients, especially given that there are limited treatment options for this type of advanced cancer." Phase 3 Trial Results This international, Phase 3 trial compared sunitinib to placebo in patients with progressive, well-differentiated, malignant pancreatic islet cell tumours who had progressed in the last 12 months. Patients were randomized to either the sunitinib (n=75) (37.5 mg/day, continuous daily dosing) plus best supportive care arm or the placebo plus best supportive care arm (n=79). Results showed that median PFS was 11.1 months in patients treated with sunitinib compared to 5.5 months in patients treated in the placebo arm (Hazard ratio 0.397, pAbout Pancreatic Islet Cell Tumours In contrast to exocrine pancreatic adenocarcinoma, pancreatic islet cell tumours are rare, indolent tumours of the endocrine pancreas with an incidence of two to four people per million annually worldwide. Pancreatic islet cell tumours include insulinomas, glucagonomas and gastrinomas. Current treatment options are limited. About Sutent(®) (sunitinib malate) Sutent, an oral multi-kinase inhibitor, is currently approved for both advanced renal cell carcinoma (RCC) and second-line gastrointestinal stromal tumour (GIST), based on efficacy and safety data from large, randomized Phase 3 clinical trials. Sutent works by blocking multiple molecular targets implicated in the growth, proliferation and spread of cancer. Two important Sutent targets, vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), are expressed by many types of solid tumours and are thought to play a crucial role in angiogenesis, the process by which tumours acquire blood vessels, oxygen and nutrients needed for growth. Sutent also inhibits other targets important to tumour growth, including KIT, FLT3 and RET. Important Sutent(®) (sunitinib malate) Safety Information Women of child bearing age who are (or become) pregnant during therapy should be informed of the potential for foetal harm while on Sutent. Decreases in left ventricular ejection fraction (LVEF) to below the lower limit of normal (LLN) have been observed. Patients with concomitant cardiac conditions should be carefully monitored for clinical signs and symptoms of congestive heart failure. Patients should be monitored for hypertension and treated as needed with standard antihypertensive therapy. Complete blood counts (CBCs) with platelet count and serum chemistries should be performed at the beginning of each treatment cycle for patients receiving treatment with Sutent. The most common adverse reactions in advanced RCC and GIST clinical trials were fatigue, asthenia, diarrhea, nausea, mucositis/stomatitis, ONC09/010 vomiting, dyspepsia, abdominal pain, constipation, hypertension, rash, hand-foot syndrome, skin discoloration, altered taste, anorexia and bleeding. Pfizer Oncology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009